Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Pitcher BN"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-2 z 2
    Tytuł:
    Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
    Autorzy:
    Morrison VA; University of Minnesota and VAMC , Minneapolis, MN , USA.
    Jung SH
    Johnson J
    LaCasce A
    Blum KA
    Bartlett NL
    Pitcher BN
    Cheson BD
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2015 Apr; Vol. 56 (4), pp. 958-64. Date of Electronic Publication: 2014 Aug 13.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Lymphoma, Mantle-Cell/*drug therapy
    Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/administration & dosage ; Bortezomib/adverse effects ; Disease-Free Survival ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Fatigue/chemically induced ; Female ; Follow-Up Studies ; Humans ; Lenalidomide ; Lymphopenia/chemically induced ; Male ; Middle Aged ; Nausea/chemically induced ; Nervous System Diseases/chemically induced ; Recurrence ; Remission Induction ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Thalidomide/analogs & derivatives ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Predicting response and survival in chemotherapy-treated triple-negative breast cancer.
    Autorzy:
    Prat A; 1] Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035 Barcelona, Spain [2] Department of Medicine, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.
    Lluch A; Department of Medical Oncology and Department of Pathology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.
    Albanell J; 1] Department of Medical Oncology, Hospital del Mar, IMIM, 08003 Barcelona, Spain [2] Department of Medical Oncology, Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain.
    Barry WT; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
    Fan C; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA.
    Chacón JI; Department of Medical Oncology, Hospital Virgen de la Salud, 45004 Toledo, Spain.
    Parker JS; 1] Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA [2] Department of Genetics, University of North Carolina, Chapel Hill, NC 27519, USA.
    Calvo L; Department of Medical Oncology, Complexo Hospitalario Universitario de A Coruña, 15002 A Coruña, Spain.
    Plazaola A; Department of Medical Oncology, Onkologikoa, 20014 San Sebastián, Spain.
    Arcusa A; Department of Medical Oncology, Consorci Sanitari de Terrassa, 08225 Barcelona, Spain.
    Seguí-Palmer MA; Department of Medical Oncology, Corporació Sanitària Parc Taulí, 08208 Sabadell, Spain.
    Burgues O; Department of Medical Oncology and Department of Pathology, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain.
    Ribelles N; Department of Medical Oncology and Department of Pathology, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain.
    Rodriguez-Lescure A; Department of Medical Oncology, Hospital General de Elche, 03203 Alicante, Spain.
    Guerrero A; Department of Medical Oncology, Instituto Valenciano de Oncología (IVO), 46009 Valencia, Spain.
    Ruiz-Borrego M; Department of Medical Oncology, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
    Munarriz B; Department of Medical Oncology, Hospital Universitario La Fe, 46026 Valencia, Spain.
    López JA; Department of Medical Oncology, Hospital San Camilo, 28006 Madrid, Spain.
    Adamo B; Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035 Barcelona, Spain.
    Cheang MC; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA.
    Li Y; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA.
    Hu Z; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA.
    Gulley ML; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA.
    Vidal MJ; Translational Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Pg Vall d'Hebron, 119-129, 08035 Barcelona, Spain.
    Pitcher BN; Alliance Statistical and Data Center, Duke University, Durham, NC 27708, USA.
    Liu MC; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
    Citron ML; ProHEALTH Care Associates, LLP, Lake Success, NY 11803, USA.
    Ellis MJ; Department of Oncology, Washington University, St. Louis, MO 63130, USA.
    Mardis E; Department of Oncology, Washington University, St. Louis, MO 63130, USA.
    Vickery T; Department of Oncology, Washington University, St. Louis, MO 63130, USA.
    Hudis CA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
    Winer EP; Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
    Carey LA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA.
    Caballero R; GEICAM (Spanish Breast Cancer Research Group), 28700 Madrid, Spain.
    Carrasco E; GEICAM (Spanish Breast Cancer Research Group), 28700 Madrid, Spain.
    Martín M; 1] GEICAM (Spanish Breast Cancer Research Group), 28700 Madrid, Spain [2] Department of Medical Oncology, Instituto de Investigación Sanitaria Hospital Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, 28007 Madrid, Spain.
    Perou CM; 1] Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27519, USA [2] Department of Genetics, University of North Carolina, Chapel Hill, NC 27519, USA [3] Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27519, USA.
    Alba E; Department of Medical Oncology and Department of Pathology, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain.
    Pokaż więcej
    Źródło:
    British journal of cancer [Br J Cancer] 2014 Oct 14; Vol. 111 (8), pp. 1532-41. Date of Electronic Publication: 2014 Aug 07.
    Typ publikacji:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Survival Analysis*
    Antineoplastic Agents/*therapeutic use
    Triple Negative Breast Neoplasms/*drug therapy
    Cohort Studies ; Female ; Humans ; Middle Aged ; Treatment Outcome ; Triple Negative Breast Neoplasms/physiopathology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-2 z 2

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies